Team | Scientific and Drug Development Advisory Board

Prof. Dr. David Fisher

Chairman

David E. Fisher, MD, PhD is an internationally known researcher, clinician and academic, who is Chief of the Massachusetts General Hospital Department of Dermatology at Harvard Medical School in Boston, Massachusetts (USA).

Dr. Jeanette Wood

Vice-chairwoman

Dr. Jeanette Wood is an accomplished scientist with extensive experience in all aspects of drug discovery across multiple disease areas, including cancer.

Dr. Heidi Lane

Member

Dr. Heidi Lane is a distinguished tumor biologist, holding a PhD in Biochemistry and boasting a robust academic background, complemented by an impressive 22-year tenure in the field of cancer drug development and translational medicine.

Prof. Dr. Michael N. Hall

Member

Prof. Dr. Michael N. Hall is an American and Swiss molecular biologist and Professor at the Biozentrum of the University of Basel. He earned a Ph.D. in Molecular Genetics from Harvard University in 1981 and was a postdoctoral fellow at the Institut Pasteur in Paris and the University of California, San Francisco.

Dr. Doriano Fabbro

Member

Dr. Doriano Fabbro is a renowned drug discovery and kinase expert with more than 20 years’ experience in the pharmaceutical industry, following 10 years in academia. Until 2005, Doriano was an Executive Director for the Oncology Drug Discovery Division of the Novartis Institute for Biomedical Research (NIBR) in Basel, Switzerland and was a member of the NIBR Oncology Advisory Board overseeing the oncology portfolio from target discovery to clinical development.

Prof. Dr. Anton Stuetz

Member

Prof. Dr. Anton Stuetz is a medicinal chemist and pharmacologist with more than 40 years of experience in Pharmaceutical Research and Development in the fields of antifungal chemotherapy, immunology, oncology, inflammation, dermatology, wound healing and translational research. Anton studied chemistry and physics at the University of Vienna and holds a Ph.D. in Organic Synthesis.

Dr. Paul Hebeisen

Member

Dr. Paul Hebeisen is a highly experienced medicinal chemist with an impressive track record in drug discovery over 28 years of service at F. Hoffmann-La Roche AG, Switzerland. Paul served in various positions, most notably as a Group Leader in Chemistry in the discovery of novel anti-infectives.

Prof. Dr. Bernd Giese

Member

Prof. Dr. Bernd Giese is a professor of organic chemistry and co-founder and former chairman of the biotech company Piqur Therapeutics AG. He studied the influence of activation entropies on the selectivity of organic reactions and developed the isoselective relationship.

Dr. Marc Lang

Member

Dr. Marc Lang is a medicinal chemist with an outstanding career served in Novartis, Basel, Switzerland and spanning more than 30 years in drug discovery across various therapeutic fields, including infectious diseases and oncology. Marc contributed personally to the discovery of three compounds that were successfully developed and approved to treat patients (Femara, Reyataz and Tasigna).